
High-titer AAV disrupts cerebrovascular integrity and induces lymphocyte infiltration in adult mouse brain
Brief intro:
- Author: Yaowei Guo, Junliang Chen, Wenyu Ji, Liang Xu, Yu Xie, Shu He, Chuying Lai, Kaiyu Hou, Zeru Li, Gong Chen and Zheng Wu
- Journal: Mol Ther Methods Clin Dev
- Doi: https://www.doi.org/10.1016/j.omtm.2023.08.021
- Publication Date: 2023 Aug 28
Products/Services used in the paper
Quotation shows PackGene:AAV vector production and titration SsAAV vectors were used in this study, and all vector genomes were flanked by AAV2/9 (AAV9) or AAV2/5 (AAV5) ITRs. AAV vectors, GFAP-GFP and CAG-Flex-GFP, were constructed by PackGene Biotech. The versions of the GFAP promoter used in this study included GFAP2.2 (2.2-kb gfa2 promoter), GFAP1.6 (1.6-kb GFAP promoter), and GFAP681 (681-bp gfaABC1D promoter). Recombinant AAV9 and AAV5 were produced by PackGene Biotech
Research Field:CNS
AAV Serotype:AAV5, AAV9
Targeted organ:brain
Animal or cell line strain:mouse
Abstract
The brain is often described as an “immune-privileged” organ due to the presence of the blood-brain-barrier (BBB), which limits the entry of immune cells. In general, intracranial injection of adeno-associated virus (AAV) is considered a relatively safe procedure. In this study, we discovered that AAV, a popular engineered viral vector for gene therapy, can disrupt the BBB and induce immune cell infiltration in a titer-dependent manner. First, our bulk RNA sequencing data revealed that injection of high-titer AAV significantly upregulated many genes involved in disrupting BBB integrity and antiviral adaptive immune responses. By using histologic analysis, we further demonstrated that the biological structure of the BBB was severely disrupted in the adult mouse brain. Meanwhile, we noticed abnormal leakage of blood components, including immune cells, within the brain parenchyma of high-titer AAV injected areas. Moreover, we identified that the majority of infiltrated immune cells were cytotoxic T lymphocytes (CTLs), which resulted in a massive loss of neurons at the site of AAV injection. In addition, antagonizing CTL function by administering antibodies significantly reduced neuronal toxicity induced by high-titer AAV. Collectively, our findings underscore potential severe side effects of intracranial injection of high-titer AAV, which might compromise proper data interpretation if unaware of.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
